LETTERS
IMAJ | volume 28
Journal 2, February 2026
pages: 133
Merkel cell carcinoma in Israel: Beilinson's experience
1 Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel
2 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
Summary
We read with great interest the article by Toledano and colleagues [1] about Merkel cell carcinoma (MCC). The authors describe demographic and tumor characteristics of 17 patients seen at Shaare Zedek Medical Center between 2015 and 2022.
The authors claim that “data on MCC, especially from tertiary centers in Israel, is limited,” without providing a reference to document their statement. We would like to argue the opposite.